ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

244
Analysis
Health Care • India
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
•17 May 2025 09:32•Broker

HSIE Results Daily: Lupin, Hitachi Energy, Berger Paints, Apollo Tyres

Lupin: EBITDA was up 30% YoY, led by 11% YoY sales growth (US: +4% QoQ, India +7% YoY) and higher GM (+197 bps YoY), which was partly offset by...

Logo
408 Views
Share
•14 May 2025 19:34•Broker

Pharmaceuticals: US to cut Rx drug price, no impact on generics

The US president Donald Trump signed an “Executive Order” (EO) to bring the prices for prescription (Rx) drugs in line with other developed nations

Logo
163 Views
Share
bullish•Cipla Ltd
•12 May 2025 07:20

India: Potential Free Float Changes & Passive Flows in 3 Weeks

Changes to shareholding patterns could lead to changes in float for some stocks in local/global indices. Passive trackers will need to trade over 3...

Logo
528 Views
Share
•11 May 2025 08:30

APAC Healthcare Weekly (May 11)- Shionogi, Daiichi Sankyo, HK Inno, Neuren, Biocon, Aster DM, Lupin

Shionogi is acquiring Torii Pharma. Daiichi Sankyo’s Enhertu meets key goal in breast cancer trial. HK inno got domestic approval for P3 trial of...

Logo
611 Views
Share
•27 Apr 2025 08:30

APAC Healthcare Weekly (April 27)- Sillajen, Akeso, Innovent Biologics, CSL, Daiichi Sankyo, Lupin

SillaJen got FDA nod for clinical trial indication expansion. FDA approves Akeso’s first drug. Innovent’s cancer drug was approved in China....

Logo
607 Views
Share
x